Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.12.
Source: insidermonkey.com
Martucci Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Martucci Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Martucci Johnson Today - Breaking & Trending Today
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
SAN DIEGO, Dec. 26, 2023 -- Daré Bioscience, Inc. , a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5...
Source: marketscreener.com
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript
Operator: Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update. This call is being recorded.
Source: insidermonkey.com
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July ...
Source: marketscreener.com
Vaginal tamoxifen capsule safe for postmenopausal vulvovaginal atrophy
Treatment with a vaginal tamoxifen capsule in postmenopausal women with moderate to severe vulvovaginal atrophy was safe with minimal drug exposure, researchers reported in a phase 1/2 clinical study.The vaginal tamoxifen capsule, DARE-VVA1 (Daré Bioscience), is a soft gelatin capsule containing tamoxifen to treat vulvovaginal atrophy without hormones in postmenopausal women.
Source: healio.com